Associate Professor, Hematology and Medical Oncology, Winship Cancer Institute of Emory University
Hematology
Dr. Martha L. Arellano, MD
|
|
Give Review
Martha Arellano is an expert in the field of Hematology. She went to Emory University School of Medicine. Emory University School of Medicine is ranked 23 in research and 42 in primary care medicine Martha L. Arellano, MD is also published. She has 32 publications published. The lastest publication: "6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.' Doctor Martha L. Arellano, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
- Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed Acute leukemia or high-risk myelodysplastic syndrome.
- Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth.
- Predicting early blast transformation in chronic-phase chronic myeloid Leukemia: Is immunophenotyping the missing link?
- Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the warburg effect.
- Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth.
- Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex.
- Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhi...
- Epsilon aminocaproic acid prevents bleeding in severely Thrombocytopenic patients with hematological malignancies.
- Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.
- Oral sapacitabine for the treatment of Acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
- Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for VTE prophylaxis?
- Tools to optimize the functionality of a Leukemia clinical trial team.
- Early clearance of peripheral blood blasts predicts response to induction chemotherapy in Acute myeloid leukemia.
- Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
- Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor Cell transplantation.
- Treatment of relapsed Acute leukemia after allogeneic transplantation: a single center experience.
- Update on optimal management of Acute myeloid leukemia.
- Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation.
- Phase II study of clofarabine monotherapy in previously untreated older adults with Acute myeloid leukemia and unfavorable prognostic factors.
- Efficacy of dasatinib for the treatment of intractable chronic myeloid Leukemia.
- Clinical uses of GM-CSF, a critical appraisal and update.
- Granulocyte-macrophage-colony-stimulating factor and other cytokines: as adjuncts to Cancer immunotherapy, stem cell transplantation, and vaccines.
- Regulation of alloImmune responses by dendritic cell subsets.
- Prognostic significance of leukopenia at the time of diagnosis in Acute myeloid leukemia.
- Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid Leukemia?
- High-dose cytarabine induction is well tolerated and active in patients with de novo Acute myeloid leukemia older than 60 years.
- Deep venous thromboses in patients with hematological malignancies after peripherally inserted Central venous catheters.
- Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of ...
- Peripheral blood monitoring of chronic myeloid Leukemia during treatment with imatinib, second-line agents, and beyond.
- Long-term progression-free survival after early autologous transplantation for mantle-cell Lymphoma.
Schools
Emory University School Of Medicine
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Breast Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Emory University -
Emory University School of Medicine
Hospital
-
Emory University Hospital -
Emory University Hospital Midtown -
Grady Memorial Hospital
Drug Facts
| NPI NUMBER | 1952310500 | |
| NPPES Provider LastName | ARELLANO | |
| NPPES Provider FirstName | MARTHA | |
| NPPES Provider ZIPCode | 303221013 | |
| NPPES Provider State | GA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 916.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 17.0 | |
| Percent Opioid Claims | 1.86 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952310500 |
| Last Name Of The Provider | ARELLANO |
| First Name Of The Provider | MARTHA |
| View All |
Similar Doctors
|
|
Dr. Ha N. Tran, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pradeep C. Jolly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fadlo R. Khuri, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Sujatha Murali, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ana G. Antun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephanie D. Schniederjan, MD |
|
|
Dr. Angelica G. James-Herry, MD |
|
|
Dr. John S. Kauh, MD |
|
|
Dr. Vikas A. Gupta, MD |
|
|
Dr. Abbie L. Husman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary J. Lechowicz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Amy Gartner, CPNP |